Naltrexone is under clinical development by Allodynic Therapeutics and currently in Phase II for Migraine. According to GlobalData, Phase II drugs for Migraine have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Naltrexone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Naltrexone is under development for the treatment of postherpetic neuralgia, migraine, adjustment disorder (emotional pain). The drug candidate acts by targeting opioid receptors.
For a complete picture of Naltrexone’s drug-specific PTSR and LoA scores, buy the report here.